Cum Pietriș vraja bcl2 marker prognostic role balon recruta Încorporarea
Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings - Annals of Oncology
Targeting BCL-2 regulated apoptosis in cancer | Open Biology
Quantitative analysis of tumor-specific BCL2 expression in DLBCL: refinement of prognostic relevance of BCL2 | Scientific Reports
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment - ScienceDirect
Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin | PLOS ONE
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received | British Journal of Cancer
Bcl-2 - Wikipedia
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment - ScienceDirect
PDF) BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received | ResearchGate
Noncanonical Cell Fate Regulation by Bcl-2 Proteins: Trends in Cell Biology
A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy | Cell Death & Disease
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance | Cell Death & Disease
Dysregulation of BCL-2 family proteins by leukemia fusion genes - Journal of Biological Chemistry
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia | Haematologica
bcl-2 expression in head and neck cancer: an enigmatic prognostic marker - International Journal of Radiation Oncology, Biology, Physics
Bcl-2 as a clinical prognostic marker. | Download Table
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received | British Journal of Cancer
Frontiers | Targeting the Bcl-2 Family in B Cell Lymphoma
Targeting BCL2 for the Treatment of Lymphoid Malignancies - ScienceDirect
IVD Antibody Development Services for BCL-2 Marker - Creative Biolabs
Bcl-2 as a clinical prognostic marker. | Download Table
Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: A retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant
Cancers | Free Full-Text | Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis - Clinical Lymphoma, Myeloma and Leukemia
Targeting BCL2 for the Treatment of Lymphoid Malignancies - ScienceDirect
IJMS | Free Full-Text | Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer | HTML
Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL - ScienceDirect